Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
News|Articles|February 23, 2017
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-03-01-2017
- Volume 12
- Issue 3
Novasep Opens New Bioconjugation Unit in France
Author(s)Pharmaceutical Technology Editors
The company opened a new bioconjugation unit to support the clinical and commercial manufacturing of ADCs.
Advertisement
On Feb. 23, 2017, Novasep announced the opening of its new €11-million (approximately $11.64 million) bioconjugation unit in the company’s Le Mans site in France. The 2000m2 facility includes two flexible good manufacturing practice (GMP) production suites equipped with 10L to 400L vessels to support both clinical and commercial manufacturing of antibody-drug conjugates. The stand-alone facility is purpose-built and offers R&D services, quality control, and scale-up laboratories.
“Our team has a long experience in applying DoE to chemical synthesis and bioprocessing and efficiently develop conjugation, and purification steps on a wide range of ADC platforms,” said Rachel de Luca, general manager of Le Mans site in a
Source:
Articles in this issue
over 9 years ago
Viewpoint: No Clear Path for Pharma or Outsourcingover 9 years ago
Standards Set Excipient GMPs, But Collaboration is Neededover 9 years ago
Monitoring Supply Chain Risk on a Limited Budgetover 9 years ago
Evaluating E&L Studies for Single-Use Systemsover 9 years ago
PfizerCentreOne Expands Fill/Finish Services in Michiganover 9 years ago
Metrohm USA Announces Winner of Young Chemist Awardover 9 years ago
Recipharm Completes Kemwell AcquisitionAdvertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement